Clinical Trial: Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Double-Blind, Placebo-Controlled, Randomized, Clinical Study of the Effects of Betaserc® 24 mg (1 Tablet b.i.d Over 3 Months) on Vestibular Compensation Following Vestibular Neurotomy in Patien

Brief Summary: This study is to compare the effects of Betaserc 24mg and placebo on compensation of postural and locomotor deficits (static and dynamic posturography) after vestibular neurotomy in patients suffering from disabling Menière's disease.

Detailed Summary:
Sponsor: Solvay Pharmaceuticals

Current Primary Outcome: Patients who have undergone vestibular neurotomy for the treatment of disabling Menière’s disease and who have confirmed vestibular areflexia

Original Primary Outcome:

Current Secondary Outcome: Other peripheral vestibular disease than Menière’s disease;Central vestibular disease; Neurological disease; Contraindication to betahistine; Pregnant or lactating women

Original Secondary Outcome:

Information By: Solvay Pharmaceuticals

Dates:
Date Received: September 9, 2005
Date Started: January 2003
Date Completion:
Last Updated: December 21, 2006
Last Verified: December 2006